Response Genetics zusammenarbeit mit GlaxoSmithKline - 500 Beiträge pro Seite

[UH1d]

Leider noch kein Thread vorhanden
Sollte man beobachten, meine Meinung

-Response Genetics, Inc. (Nasdaq:RGDX - News), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed an amended and restated master service agreement with GlaxoSmithKline, Ltd. (NYSE:GSK - News). This agreement extends the current agreement between the companies for a two-year period and names Response Genetics as preferred provider of genetic testing services to GlaxoSmithKline and its affiliated companies. In anticipation of 2009 services, GlaxoSmithKline agreed to make an upfront payment to Response Genetics of $1.3 million before the end of 2008.

ADVERTISEMENT
“We are very pleased to continue supporting GlaxoSmithKline’s clinical trial development program,” said Kathleen Danenberg, Response Genetics’ president and CEO. “Our collaborative relationship underscores the value our service and patented technology brings to pharmaceutical partners like GlaxoSmithKline, in helping them develop new cancer-fighting therapies.”

Response Genetics’ patented diagnostic technology and services are also commercially available to physicians through the company’s ResponseDX: Lung™ and ResponseDX: Colon™ tests. By providing information on a panel of molecular markers, these PCR-based genetic tests can help physicians with therapeutic treatment decisions in patients with non-small cell lung cancer and colorectal cancer.




http://www.responsegenetics.com/


Handeln besser in USA hier kein Volumen

[UH1d]

Response Genetics Signs Agreement With Roche Diagnostics to Support Cancer Test Development

* Tuesday February 3, 2009, 8:30 am EST

* Yahoo! Buzz
* Print

Related:

* Response Genetics, Inc

LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq:RGDX - News), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today it has signed a nonexclusive license with Roche Diagnostics for the use of Response Genetics’ patented PCR analysis to assess human epidermal growth factor type 2 (HER2) gene expression. The accurate measurement of HER2 gene expression can assist physicians with treatment decisions for patients with cancers in tissues such as breast.
Related Quotes
Symbol Price Change
RGDX 1.50 0.00
Chart for Response Genetics, Inc.
{"s" : "rgdx","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“We are extremely pleased to be working with Roche to help make personalized medicine a reality for cancer patients,” said Kathleen Danenberg, Response Genetics’ president and CEO. “This agreement strengthens our long relationship with Roche and fulfills a promise we made during our initial public offering to license our intellectual property while protecting our intellectual capital freedom.”

Results from a recent study presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) found that women with HER2-positive gene expression have a three times higher risk of recurrence, even if the cancer is caught in the early stages.1 HER2 gene amplification has been shown to correlate with improved clinical outcome in response to certain cancer drugs, and its measurement by RT PCR was recently shown to correlate with analyses by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC).2

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (the “Company”) (Nasdaq:RGDX - News) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.